Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Exosome protein CD82, GPC1-combined CA19-9 for pancreatic cancer early diagnosis and curative effect monitoring

A technology of exosomes and pancreatic cancer, applied in the field of medical biological detection, can solve the problem of not fully representing the condition of pancreatic cancer

Active Publication Date: 2019-02-12
SHANGHAI BIOTECAN PHARMA +1
View PDF10 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, the diagnosis of pancreatic cancer mainly relies on imaging examinations, and CA19-9 cannot fully represent the condition of pancreatic cancer; Exo-GPC1+ for early diagnosis of pancreatic cancer is only in the research stage

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Exosome protein CD82, GPC1-combined CA19-9 for pancreatic cancer early diagnosis and curative effect monitoring
  • Exosome protein CD82, GPC1-combined CA19-9 for pancreatic cancer early diagnosis and curative effect monitoring
  • Exosome protein CD82, GPC1-combined CA19-9 for pancreatic cancer early diagnosis and curative effect monitoring

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0191] Embodiment 1: preparation kit of the present invention

[0192] The kit of the present invention consists of the following:

[0193] A) CA19-9 assay contains reagents

[0194] 1) R1: Access CA19-9 kit (Access CA19-9 kit was purchased from Beckman (Access® GIMonitor - 2 packs of 50 tests / pack Cat#387687)): 50 tests / box;

[0195] 2) R1a: magnetic particles coated with biotin-labeled goat anti-CA19-9 monoclonal antibody;

[0196] 3) R1b: Goat anti-CA19-9 monoclonal antibody labeled with alkaline phosphatase;

[0197] 4) R2: Neutral detergent.

[0198] 5) S1~S6: Access CA19-9 calibrators include S1, S2, S3, S4, S5, S6:, the concentrations of CA19-9 contained in them are 0, 30, 90, 300, 900, 2000U / ml respectively .

[0199] B) Detection reagents for GPC1 and CD82 protein expression in exosomes:

[0200] 1) Exosome isolation: Density gradient medium-1 (Density gradient medium-1) 6ml

[0201] 2) Density gradient medium-2 (Density gradient medium-2) 6ml

[0202] 3) Dens...

Embodiment 2

[0219] Embodiment 2: the detection method of the kit of embodiment 1

[0220] 1. Blood sample collection and sample preparation:

[0221] Due to the advantages of convenient, non-invasive, and continuous detection of peripheral blood, the use of peripheral blood to detect pancreatic cancer diagnostic biomarkers can detect the occurrence of pancreatic cancer early, and improve the early clinical diagnosis of pancreatic cancer to a new level.

[0222]Blood samples were collected from Datong Tongmei Hospital in Shanxi, Hebei Provincial People's Hospital, and Shanghai Sixth People's Hospital: 24 healthy volunteers and 26 pancreatic cancer patients. Sample collection: Collect about 3-6 ml of peripheral blood from the patient and put it into a vacuum coagulation tube, invert it several times to fully combine, let it stand for about half an hour, centrifuge at 1600g for 10 minutes, and transfer the supernatant to a new tube. The supernatant was centrifuged at 12000 g for 10 min for ...

Embodiment 3

[0266] Example 3: Logistic regression analysis and ROC curve analysis of peripheral blood CA19-9 content, Exo-CD82+ and Exo-GPC1+ expression in healthy people and pancreatic cancer patients

[0267]The present invention detected the content of CA19-9 and the expression levels of Exo-GPC1+ and Exo-CD82+ in the serum of 26 healthy people and 24 patients with pancreatic cancer. Through logistic regression and ROC curve analysis, it was found that CA19-9, Exo-GPC1+ and Exo- CD82+ combined diagnosis of pancreatic cancer has the most significant AUC 联合诊断 =0.942, P CA19-9 =0.7340, P GPC1 =0.8846, P CD82 =0.8518, P <0.01) were also superior to CA19-9 diagnosis alone (Table 2).

[0268] Table 2 ROC analysis of combined diagnosis of peripheral blood CA19-9, Exo-CD82+ and Exo-GPC1+ in healthy people and pancreatic cancer patients

[0269]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medical biological detection, in particular to a multi-index combined detection, a detection kit and a detection method for early diagnosis and curativeeffect monitoring of pancreatic cancer. The indexes comprise an exosome CD82 protein expression quantity, an exosome GPC1 protein expression quantity and CA19-9 content. The latest exosome protein markers are combined for detection, so that the defects of relatively low detection sensitivity and specificity of the single index CA19-9 are overcome, so that the diagnosis result is more accurate andeffective. The method provides a novel method for early diagnosis and curative effect monitoring detection of pancreatic cancer, and is used for realizing early diagnosis and early treatment of pancreatic cancer, the diagnosis and treatment efficiency is improved, the life of a patient is prolonged, and a foundation is laid for improving the prognosis.

Description

technical field [0001] The invention relates to the technical field of medical biological detection, specifically, a combination of Exo-CD82+ (exosome CD82 protein expression), Exo-GPC1+ (exosome GPC1 protein expression), CA19-9, and detection. The detection kit and the detection method thereof are used for the early diagnosis and curative effect monitoring of pancreatic cancer. Background technique [0002] Pancreatic cancer is one of the most common malignant tumors in the world, with a very high mortality rate, and its 5-year survival rate is only 3%. Survival rates for patients with pancreatic cancer have not improved in nearly 40 years. The incidence of pancreatic cancer in my country is on the rise, and the number of cases in 2015 reached about 90,100. Due to the lack of specific tumor markers in pancreatic cancer, it is difficult to achieve early diagnosis and large-scale population screening of pancreatic cancer only by traditional imaging methods. 15% of patients...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/574G01N33/68
CPCG01N33/57438G01N33/57488G01N33/6803
Inventor 甄林青吴唯维赵小玉何章勇许骋楼敬伟
Owner SHANGHAI BIOTECAN PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com